Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Implications of IMW 2019 on nursing practices

Tanya Burton • 14 Sep 2019
IMW 2019
Amyloidosis Multiple Myeloma Rare Diseases Dexamethasone

Tanya Burton University Hospital of Wales, Cardiff, UK, shares her highlights and reflections from the nursing symposium attached to the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Tanya Burton

Multiple myeloma: what needs to change to improve care?
1:03
Multiple myeloma: what needs to change to improve care?
Tanya Burton • 2 Apr 2019
Self-administration of bortezomib in multiple myeloma: results from Cardiff
2:18
Self-administration of bortezomib in multiple myeloma: results from Cardiff
Tanya Burton • 2 Apr 2019
Approval of Dvd for myeloma at first relapse in the UK: impacts on care
0:40
Approval of Dvd for myeloma at first relapse in the UK: impacts on care
Tanya Burton • 2 Apr 2019

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Tanya Burton • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Tanya Burton • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Tanya Burton • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Tanya Burton • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals